630 related articles for article (PubMed ID: 30068361)
1. Targeting the IDO1 pathway in cancer: from bench to bedside.
Liu M; Wang X; Wang L; Ma X; Gong Z; Zhang S; Li Y
J Hematol Oncol; 2018 Aug; 11(1):100. PubMed ID: 30068361
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor.
Song X; Si Q; Qi R; Liu W; Li M; Guo M; Wei L; Yao Z
Front Immunol; 2021; 12():800630. PubMed ID: 35003126
[TBL] [Abstract][Full Text] [Related]
6. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.
Peng X; Zhao Z; Liu L; Bai L; Tong R; Yang H; Zhong L
Drug Des Devel Ther; 2022; 16():2639-2657. PubMed ID: 35965963
[TBL] [Abstract][Full Text] [Related]
7. Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression.
Amobi A; Qian F; Lugade AA; Odunsi K
Adv Exp Med Biol; 2017; 1036():129-144. PubMed ID: 29275469
[TBL] [Abstract][Full Text] [Related]
8. A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression.
Klar R; Michel S; Schell M; Hinterwimmer L; Zippelius A; Jaschinski F
Cancer Immunol Immunother; 2020 Jan; 69(1):57-67. PubMed ID: 31802183
[TBL] [Abstract][Full Text] [Related]
9. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
10. Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.
Yuasa HJ; Ball HJ; Ho YF; Austin CJ; Whittington CM; Belov K; Maghzal GJ; Jermiin LS; Hunt NH
Comp Biochem Physiol B Biochem Mol Biol; 2009 Jun; 153(2):137-44. PubMed ID: 19402226
[TBL] [Abstract][Full Text] [Related]
11. The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment.
Gostner JM; Becker K; Überall F; Fuchs D
Expert Opin Ther Targets; 2015 May; 19(5):605-15. PubMed ID: 25684107
[TBL] [Abstract][Full Text] [Related]
12.
Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
[TBL] [Abstract][Full Text] [Related]
13. Targeting the IDO1/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities.
Cheong JE; Sun L
Trends Pharmacol Sci; 2018 Mar; 39(3):307-325. PubMed ID: 29254698
[TBL] [Abstract][Full Text] [Related]
14. miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy.
Huang Q; Xia J; Wang L; Wang X; Ma X; Deng Q; Lu Y; Kumar M; Zhou Z; Li L; Zeng Z; Young KH; Yi Q; Zhang M; Li Y
J Hematol Oncol; 2018 Apr; 11(1):58. PubMed ID: 29685162
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
16. Heme-containing enzymes and inhibitors for tryptophan metabolism.
Yan D; Lin YW; Tan X
Metallomics; 2017 Sep; 9(9):1230-1240. PubMed ID: 28650043
[TBL] [Abstract][Full Text] [Related]
17. The role of IDO in brain tumor immunotherapy.
Zhai L; Lauing KL; Chang AL; Dey M; Qian J; Cheng Y; Lesniak MS; Wainwright DA
J Neurooncol; 2015 Jul; 123(3):395-403. PubMed ID: 25519303
[TBL] [Abstract][Full Text] [Related]
18. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
19. IDO1/TDO dual inhibitor RY103 targets Kyn-AhR pathway and exhibits preclinical efficacy on pancreatic cancer.
Liang H; Li T; Fang X; Xing Z; Zhang S; Shi L; Li W; Guo L; Kuang C; Liu H; Yang Q
Cancer Lett; 2021 Dec; 522():32-43. PubMed ID: 34520819
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin promotes T-cell proliferation by inhibiting the expression and enzymatic activity of immunosuppressive indoleamine-2,3-dioxygenase in human breast cancer cells.
Ebokaiwe AP; Njoya EM; Sheng Y; Zhang Z; Li S; Zhou Z; Qiang Z; Peng T; Hussein AA; Zhang G; Lu X; Li L; Wang F
Toxicol Appl Pharmacol; 2020 Oct; 404():115203. PubMed ID: 32822738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]